Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
暂无分享,去创建一个
M. Dowsett | S. Ebbs | J. Blohmer | I. Smith | S. Ashley | G. Walsh | J. Dixon | S. Francis | A. Skene | I. Boeddinghaus | I. Smith
[1] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.
[2] J. Dixon,et al. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[3] J. Dixon,et al. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. , 2002, European journal of cancer.
[4] J. Dixon,et al. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer , 2002, British Journal of Cancer.
[5] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[6] J. Dixon,et al. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. , 2002, Cancer control : journal of the Moffitt Cancer Center.
[7] M. Dowsett,et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Baum. Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group) , 2002 .
[9] M. Ellis,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Boni,et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Robertson,et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Buzdar,et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Dixon,et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] M. Dowsett,et al. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. , 1995, British Journal of Cancer.
[16] U. Chetty,et al. Indications for primary tamoxifen therapy in elderly women with breast cancer , 1992, The British journal of surgery.
[17] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .